Jiangsu Hengrui Pharmaceuticals (01276): HRS-7525 tablets obtained drug clinical trial approval notification.
Hengrui Medicine (01276) announces that recently, Jiangsu Hengrui Medicine Co., Ltd. (hereinafter referred to as the "Company") has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") for HRS-7525 tablets, and will conduct clinical trials in the near future.
Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Company") has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (referred to as "NMPA"), and will soon begin clinical trials for HRS-7525 tablets.
HRS-7525 tablets are innovative anti-tumor drugs independently developed by the Company, intended for the treatment of solid tumor patients. As of now, there are no similar products approved for marketing in China. Up to now, the accumulated research and development investment in the HRS-7525 tablet project is approximately 24.6 million yuan (unaudited).
Related Articles
MeiG Smart Technology (03268) plans to pay a final dividend of HKD 1 for every 10 shares.
.png)
UNITED LAB (03933) spent HK$4.1832 million on repurchasing 500,000 shares on June 16th.
CSTONE PHARMA-B (02616) spent 6.2278 million Hong Kong dollars to repurchase 1.33 million shares on June 16th.
MeiG Smart Technology (03268) plans to pay a final dividend of HKD 1 for every 10 shares.
UNITED LAB (03933) spent HK$4.1832 million on repurchasing 500,000 shares on June 16th.
CSTONE PHARMA-B (02616) spent 6.2278 million Hong Kong dollars to repurchase 1.33 million shares on June 16th.
RECOMMEND
